Pages that link to "Q27853136"

The following pages link to Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. (Q27853136):

Displaying 33 items.

• Crizotinib resistance: implications for therapeutic strategies (Q26738381) (← links)
• Tackling ALK in non-small cell lung cancer: the role of novel inhibitors (Q26740329) (← links)
• Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs (Q26769659) (← links)
• Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells (Q26774625) (← links)
• CIViC database (Q27612411) (← links)
• The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma (Q27853241) (← links)
• Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice (Q27853373) (← links)
• ALK ALK Fusion G1202R (Q28371081) (← links)
• ALK NPM::ALK (Q28371469) (← links)
• ALK ALK Fusion G1269A (Q28371512) (← links)
• Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma (Q30239901) (← links)
• Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation (Q37003600) (← links)
• Resisting Resistance: Targeted Therapies in Lung Cancer (Q37388238) (← links)
• The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer (Q38558178) (← links)
• NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 (Q38902511) (← links)
• Ceritinib: a Review in ALK-Positive Advanced NSCLC. (Q38971602) (← links)
• Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview (Q38989374) (← links)
• Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer (Q39278116) (← links)
• TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. (Q41133791) (← links)
• A genome-wide microRNA profiling indicates miR-424-5p and miR-503-5p as regulators of ALK expression in neuroblastoma. (Q41346041) (← links)
• Current and future treatment of anaplastic lymphoma kinase-rearranged cancer (Q42012859) (← links)
• Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. (Q47578326) (← links)
• Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib (Q47777234) (← links)
• Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. (Q52679023) (← links)
• Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations. (Q55693260) (← links)
• SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics (Q58101254) (← links)
• Targeted therapies for advanced non-small cell lung cancer (Q61455097) (← links)
• Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9 (Q89360019) (← links)
• Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers (Q92028093) (← links)
• Role of liquid biopsy in oncogene-addicted non-small cell lung cancer (Q92134595) (← links)
• Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma (Q92152007) (← links)
• Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies (Q92307894) (← links)
• Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report (Q95260382) (← links)